Picture EBD Group BIO-Europe Spring 2021 Digital 650x80
Organisation › Details

Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents. The company was registered in 1999 and is located in Uppsala, Sweden. *


Period Start 0199-01-01 established
Products Industry cancer drug
Persons Person Martelet, Francois R. (Oasmia 202008 CEO before TopoTarget 201011 CEO)
  Person 2 af Winklerfelt, Michael (Oasmia 202008 CFO)
Region Region Uppsala
  Country Sweden
  Street 1 Vallongatan
  City 725 28 Uppsala
  Tel +46-18-505440
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: 
Record changed: 2020-09-08


Picture [iito] Plain Stupid Simple 650x80px

More documents for Oasmia Pharmaceutical AB

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Back into Ad 650x80px

» top